PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 211
- Registration Number
- NCT06698796
A Study to Learn About if the Study Medicine Called Ibuzatrelvir Changes How the Body Process the Other Medicine Dabigatran Etexilate in Healthy Adults
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT06693518
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Study to Learn How Different Amounts of the Study Medicine Called PF-08049820 Are Tolerated and Act in the Body in Healthy Adults
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 21
- Registration Number
- NCT06686797
- Locations
- 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States
Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey
Active, not recruiting
- Conditions
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1363
- Registration Number
- NCT06680206
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2330
- Registration Number
- NCT06679140
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT06678555
- Locations
- 🇨🇳
Pfizer, Taipei, Taiwan
A Study to Learn More About the Study Medicine PF-07275315 in Healthy Chinese Adult Participants
- First Posted Date
- 2024-11-05
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT06675188
A Study to Learn About the Study Medicine Called PF-07905428 in Healthy Participants and Participants With Acne Vulgaris
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 52
- Registration Number
- NCT06671834
- Locations
- 🇨🇦
InnovaDerm, Montreal, Quebec, Canada
A Study to Learn How Different Forms of the Study Medicine Called PF-07976016 Are Taken Up Into the Blood in Healthy Adults
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-01
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT06670170
- Locations
- 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States
A Study to Learn How Different Tablets of the Study Medicine Mevrometostat Are Taken up Into the Blood in Healthy Adults
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT06661694
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
© Copyright 2024. All Rights Reserved by MedPath